GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer

/in , , /by

A new investigational agent code‑named GLR2037 has entered early clinical development as a first‑in‑human phase 1 study in patients with advanced prostate cancer, representing a significant step in the evolution of androgen receptor–directed therapies. GLR2037 is an androgen receptor (AR)–targeting proteolysis‑targeting chimera (PROTAC), designed not merely to inhibit the AR but to promote its ubiquitin‑proteasome–mediated […]

Read more

P‑PSMA‑101 CAR‑T Therapy in Advanced Prostate Cancer: Early Results from a Phase 1 Trial

/in , , /by

P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]

Read more

Phase 1/2 PARTHENON Trial: AZD4956 Targets HRD in Advanced Prostate Cancer

/in , , , /by

The PARTHENON trial tests AZD4956, an experimental oral drug that blocks SMARCA2, a protein helping cancer cells rearrange their DNA to keep growing. In tumors already “weak” at fixing DNA damage due to homologous recombination deficiency (HRD), shutting down SMARCA2 creates a double hit: cells can’t remodel chromatin or repair errors, leading to collapse. This […]

Read more

Phase 1 Trial for SYS6043: A New Antibody-Drug Conjugate Targeting B7-H3

/in , , /by

SYS6043 is a new type of antibody-drug conjugate, or ADC. It zeroes in on B7-H3, a protein that is expresse by advanced tumors but almost not at all on healthy cells. The antibody part sticks to B7-H3, gets pulled inside the cancer cell, and releases a topoisomerase I inhibitor that breaks the cell’s DNA and […]

Read more

HER2 FPBMC Therapy in the AM006 Phase 1/2 Trial for Metastatic Prostate Cancer

/in , , , /by

The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]

Read more

Igermetostat Plus Enzalutamide Delivers Promising rPFS in Post-Abiraterone mCRPC

/in , , , /by

Igermetostat (XNW5004), a selective EZH2 inhibitor, pairs effectively with enzalutamide in metastatic castration-resistant prostate cancer after prior novel hormone therapy, based on phase 1b/2 results. EZH2 inhibition reverses enzalutamide resistance through epigenetic changes in castration-resistant prostate cancer models. The study endpoints focused on recommended phase 2 dose, safety, and radiographic progression-free survival. ​Eighty-four patients enrolled […]

Read more

UPLIFT Trial: Abemaciclib Safely Boosts PSMA for Better Radioligand Therapy in Advanced Prostate Cancer

/in , , , /by

The UPLIFT trial is a phase 1/2 study testing a new combo for metastatic castrate-resistant prostate cancer. Researchers at the University of California, San Francisco, designed this trial to boost the power of 177Lu-PSMA-617, a targeted radiation drug called a radioligand therapy. That drug latches onto PSMA, a protein stamped all over prostate cancer cells, […]

Read more

Early Results From a Phase 1 Trial for MRT-2359 Plus Enzalutamide in mCRPC

/in , , , /by

MRT-2359 is a daily pill that destroys certain cancer-driving proteins, including the androgen receptor (AR), MYC, and Cyclin D1, by blocking a key step in how cells read genetic instructions. This approach targets metastatic castration-resistant prostate cancer (mCRPC), where AR mutations in the ligand-binding domain (LBD) allow tumors to grow despite hormone-blocking drugs like enzalutamide. […]

Read more

Phase 1 PAnTHa Trial: mCRPC First Data

/in , , /by

²²⁵Ac‑PSMA‑Trillium (BAY3563254) is an experimental treatment that delivers targeted alpha radiation to prostate cancer cells. It combines a highly selective PSMA‑binding molecule with an albumin‑binding domain that helps it stay in the bloodstream longer and reach tumors more effectively. The radioactive component, actinium‑225, is attached using a stable Macropa chelator to increase safety and stability. […]

Read more

UPDATE: VIR-5500 Results From Phase 1 Trial Look Very Promising

/in , , /by

Recent clinical data from a Phase 1 dose-escalation trial highlight VIR-5500 as a highly promising therapeutic candidate for patients with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is a dual-masked, bispecific T-cell engager designed to selectively target the prostate-specific membrane antigen (PSMA) while minimizing systemic toxicity. The therapy employs a specialized PRO-XTEN masking technology […]

Read more